Osteonecrosis after administration of intravitreous bevacizumab

Journal of Oral and Maxillofacial Surgery

Volumn 70, Issue 3, 2012, Pages 632-635

  Hopp, Renato Nicolás ^a   Pucci, Juliana ^a   Santos Silva, Alan Roger ^a   Jorge, Jacks ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHLORHEXIDINE; CLINDAMYCIN; MOUTHWASH; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; MONOCLONAL ANTIBODY; TOPICAL ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CASE REPORT; CURETTAGE; FOLLOW UP; HISTOLOGY; HUMAN; JAW OSTEONECROSIS; JAW PAIN; MALE; MANDIBLE CURETTAGE; RETINA DISEASE; RETINA VEIN THROMBOSIS; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; INTRAVITREAL DRUG ADMINISTRATION; JAW DISEASE; MIDDLE AGED; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHLORHEXIDINE; CLINDAMYCIN; DRUG THERAPY, COMBINATION; HUMANS; INTRAVITREAL INJECTIONS; JAW DISEASES; MALE; MIDDLE AGED; MOUTHWASHES; OSTEONECROSIS; TREATMENT OUTCOME;

EID: 84859932479     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2011.02.104     Document Type: Article

References (23)

1. Bressler SB: Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 116:S1, 2009
2. Rosenfeld PJ: Intravitreal Avastin: The low cost alternative to Lucentis? Am J Ophthalmol 142:141, 2006
3. Andriolo RB, Puga ME, Belfort Júnior R, et al: Bevacizumab for ocular neovascular diseases: A systematic review. Sao Paulo Med J 127:84, 2009
4. Marrs J, Zubal BA: Oncology nursing in a new era: Optimizing treatment with bevacizumab. Clin J Oncol Nurs 13:564, 2009
5. Shih T, Lindley C: Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779, 2006
6. Serra E, Paolantonio M, Spoto G, et al: Bevacizumab-related osteonecrosis of the jaw. Int J Immunopathol Pharmacol 22: 1121, 2009
7. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81, 2008
8. Estilo CL, Fornier M, Farooki A, et al: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 20:4037, 2008
9. Greuter S, Schmid F, Ruhstaller T, et al: Bevacizumab-Associated osteonecrosis of the jaw. Ann Oncol 19:2091, 2008
10. Hou J, Tao Y, Jiang YR, et al: Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: A matched study. Chin Med J (Engl) 122:2695, 2009
11. Lim JY, Lee SY, Kim JG, et al: Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol, 2010, doi: 10.1111/j.1755-3768.2009. 01841.x
12. Fung AE, Rosenfeld PJ, Reichel E: The International intravitreal bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344, 2006
13. Mordenti J, Cuthbertson RA, Ferrara N, et al: Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536, 1999
14. Ferrara N, Hillan KJ, Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328, 2005
15. Heiduschka P, Fietz H, Hofmeister S, et al: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48:2814, 2007
16. Zhu Q, Ziemssen F, Henke-Fahle S, et al: Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115: 1750, 2008
17. Christodoulou C, Pervena A, Klouvas G, et al: Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209, 2009
18. Guarneri V, Miles D, Robert N, et al: Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181, 2010
19. Ziemssen F, Grisanti S, Bartz-Schmidt KU, et al: Off-label use of bevacizumab for the treatment of age-related macular degeneration: What is the evidence? Drugs Aging 26:295, 2009
20. Yamashita J, McCauley LK, Van Poznak C: Updates on osteonecrosis of the jaw. Curr Opin Support. J Palliat Care 4:200, 2010
21. Mirzai R, Chang C, Greenspan A, et al: The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma 36:77, 1999
22. Ruggiero S, Gralow J, Marx RE, et al: Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7, 2006
23. Assael LA: How new knowledge sounds: Developing a contemporary understanding of osteonecrosis. J Oral Maxillofac Surg 68:957, 2010